Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 10/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 2/20 | 0.41 |
| ▸ | LDHB | P07195 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21909893 | 1.00 | DGAT1 (0.44) | DGAT1SYKLCKLDHALDHB | |
| SCHEMBL23998174 | 1.00 | DGAT1 (0.44) | DGAT1SYKLCKLDHALDHB | |
| SCHEMBL19019012 | 0.88 | DGAT1 (0.46) | DGAT1SYKBRAF | |
| SCHEMBL21909903 | 0.88 | DGAT1 (0.46) | DGAT1SYKBRAF | |
| SCHEMBL23998061 | 0.88 | DGAT1 (0.46) | DGAT1SYKBRAF | |
| SCHEMBL5497005 | 0.77 | LCK (0.62) | LCKLDHABRAFKMO | |
| SCHEMBL21910309 | 0.77 | DGAT1 (0.47) | DGAT1SYKBRAF | |
| SCHEMBL23998064 | 0.77 | DGAT1 (0.47) | DGAT1SYKBRAF | |
| SCHEMBL19019015 | 0.77 | FGFR4 (0.55) | DGAT1SYK | |
| SCHEMBL21910310 | 0.77 | FGFR4 (0.55) | DGAT1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221154-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170174652-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174652-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | DGAT1 2904/4885SYK 759/4885LCK 282/4885 |
| US-10221154-B2 | Inhibitors of the fibroblast growth factor receptor | FGFR4, FGFR1, FGFR2 | DGAT1 2904/4885SYK 759/4885LCK 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.